The role of the immune response against tissue transglutaminase in the pathogenesis of coeliac disease

2004 ◽  
Vol 3 (2) ◽  
pp. 13-20 ◽  
Author(s):  
Tobias Freitag ◽  
Hendrik Schulze-Koops ◽  
Gerald Niedobitek ◽  
Gerry Melino ◽  
Detlef Schuppan
Keyword(s):  
Immune Response ◽  
Coeliac Disease ◽  
Tissue Transglutaminase

Limited role of HLA DQ2/8 genotyping in diagnosing coeliac disease

2017 ◽  
Vol 62 (1) ◽  
pp. 25-27 ◽  
Author(s):  
Siba P Paul ◽  
Matthew Hoghton ◽  
Bhupinder Sandhu
Keyword(s):  
Small Bowel ◽  
Coeliac Disease ◽  
Tissue Transglutaminase ◽  
Caucasian Population ◽  
European Guidelines ◽  
Upper Limit ◽  
Poor Understanding ◽  
Very High ◽  
Hla Dq2

The European guidelines for diagnosing coeliac disease in children were revised in 2012. These recommend that in symptomatic children, a diagnosis of coeliac disease can be made without small-bowel biopsies provided their anti-tissue transglutaminase (anti-tTG) titre is >10 times of upper-limit-of-normal (>10×ULN) and anti-endomysial antibody is positive. In order to firm up the diagnosis in these children with very high anti-tTG titre, HLA-DQ2/DQ8 should be checked and be positive. Approximately 25–40% of white Caucasian population has HLA-DQ2/DQ8 haplotype. However, only 0.1–1% of the population will develop coeliac disease. Therefore, HLA-DQ2/DQ8 testing must not be done to ‘screen’ or ‘diagnose’ children with coeliac disease. Its use by paediatricians should be limited to children with anti-tTG>10×ULN, where the diagnosis of coeliac disease is being made on serology alone. A review of case referrals made to a tertiary paediatric gastroenterology centre in Southwest England demonstrated that HLA-DQ2/DQ8 testing is being requested inappropriately both in primary and secondary care suggesting a poor understanding of its role in diagnosis of coeliac disease. This article aims to clarify the role of HLA-DQ2/DQ8 testing for clinicians working in non-specialist settings.

Role of Tissue Transglutaminase in Gliadin Binding to Reticular Extracellular Matrix and Relation to Coeliac Disease Autoantibodies

Autoimmunity ◽  
1998 ◽  
Vol 28 (4) ◽  
pp. 185-195 ◽  
Author(s):  
H. Uhlig ◽  
A. A. Osman ◽  
I. D. Tanev ◽  
J. Viehweg ◽  
T. Mothes
Keyword(s):  
Extracellular Matrix ◽  
Coeliac Disease ◽  
Tissue Transglutaminase

HLA-DQ2 and/or-DQ9 is associated with coeliac disease specific autoantibodies to tissue transglutaminase in families with thyrold autoimmunity

2001 ◽  
Vol 120 (5) ◽  
pp. A393-A393
Author(s):  
D SCHUPPAN ◽  
W DIETERICH ◽  
S HOFMANN ◽  
M HUEFNER ◽  
K USADEL ◽  
...  
Keyword(s):  
Coeliac Disease ◽  
Tissue Transglutaminase ◽  
Disease Specific ◽  
Hla Dq2

Tissue transglutaminase and coeliac disease

Endoscopy ◽  
2006 ◽  
Vol 37 (12) ◽  
Author(s):  
E Thornton ◽  
M Lynskey ◽  
J Donlon ◽  
F Stevens
Keyword(s):  
Coeliac Disease ◽  
Tissue Transglutaminase

Vitamin A: dietologist’s position

2020 ◽  
pp. 49-57
Author(s):  
S. V. Orlova ◽  
E. A. Nikitina ◽  
L. I. Karushina ◽  
Yu. A. Pigaryova ◽  
O. E. Pronina
Keyword(s):  
Immune Response ◽  
Urinary Tract ◽  
Gastrointestinal Tract ◽  
Vitamin A ◽  
Developed Countries ◽  
Therapeutic Practice ◽  
The Past ◽  
Increased Risk ◽  
Mucous Membranes

Vitamin A (retinol) is one of the key elements for regulating the immune response and controls the division and differentiation of epithelial cells of the mucous membranes of the bronchopulmonary system, gastrointestinal tract, urinary tract, eyes, etc. Its significance in the context of the COVID‑19 pandemic is difficult to overestimate. However, a number of studies conducted in the past have associated the additional intake of vitamin A with an increased risk of developing cancer, as a result of which vitamin A was practically excluded from therapeutic practice in developed countries. Our review highlights the role of vitamin A in maintaining human health and the latest data on its effect on the development mechanisms of somatic pathology.

Practical consensus recommendations - Current role of immune response evaluation criteria in solid tumors criteria in the management of cancer patients receiving immunotherapy

2019 ◽  
Vol 4 ◽  
pp. 21-23
Author(s):  
Purvish M. Parikh ◽  
T. P. Sahoo ◽  
Randeep Singh ◽  
Bahl Ankur ◽  
Talvar Vineet ◽  
...  
Keyword(s):  
Immune Response ◽  
Solid Tumors ◽  
Evaluation Criteria ◽  
Supporting Evidence ◽  
Response Evaluation ◽  
Consensus Recommendation ◽  
Current Role ◽  
New Class ◽  
Response Evaluation Criteria

Response evaluation criteria in solid tumors (RECIST) are a method used to evaluate and document the response to cancer treatment in solid tumors. The availability of a new class of immuneoncology drugs has resulted in the need to modify RECIST criteria methodology. The first leadership immuno-oncology network (LION) master course brought together experts in oncology and immuno-oncology. Six questions were put to the experts and their opinion, supporting evidence, and experience were discussed to arrive at a practical consensus recommendation. n this nascent field, the availability of a practical consensus recommendation developed by experts in the field is of immense value to the community oncologist and other health-care consultants.

Sign in / Sign up

Export Citation Format

Share Document